View of Ruxolitinib as a therapy choice for refractory pruritus in a patient with essential thrombocythemia with CALR mutation

Return to Article Details Ruxolitinib as a therapy choice for refractory pruritus in a patient with essential thrombocythemia with CALR mutation Download Download PDF